UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or o ...

Technology Development - Know Labs, Inc. is focused on the development and commercialization of proprietary sensor technologies, specifically the Bio-RFID and ChromaID platforms, which utilize electromagnetic energy for material identification and measurement [27]. - The Bio-RFID technology has successfully demonstrated the ability to non-invasively measure blood glucose levels, addressing limitations of existing optical technologies [33]. - The company plans to market two versions of its non-invasive glucose monitoring device: the KnowU (desktop version) and the UBand (wearable version), both requiring FDA clearance [35]. - Internal laboratory testing has shown a high degree of correlation between Bio-RFID technology and leading continuous glucose monitors from Abbott Labs and DexCom [36]. - The company is also exploring additional analytes for monitoring through its devices, which will require separate FDA approvals [38]. - The ChromaID technology generates unique signatures from materials using light, enabling applications in authentication and verification [39]. - Bio-RFID technology enables real-time identification of a wide range of materials and analytes, enhancing clinical diagnostics and health monitoring [50]. - The Bio-RFID platform is expected to enter the continuous glucose monitoring market, with plans to expand into other clinical monitoring markets [59]. Regulatory and Compliance - The FDA regulates the company's medical diagnostic products, including KnowU and UBand, ensuring compliance with safety and effectiveness standards [63]. - The company believes its initial product is suitable for a de novo classification request with the FDA [79]. - Regulatory approvals are necessary for some products, and there is no assurance that such approvals will be granted, which could hinder revenue generation [130]. - International regulatory clearances are required for product sales outside the U.S., and failure to obtain these could harm business operations [131]. - The company is subject to increasingly stringent foreign governmental regulations for the manufacture and sale of medical devices, which may impact international sales [132]. Financial Performance - The company reported an accumulated deficit of $101,397,738 as of September 30, 2022, with net losses of $20,071,244 and $25,360,213 for the years ended September 30, 2022 and 2021, respectively [105]. - The company completed a public offering on September 20, 2022, selling 4,140,000 shares at $2.00 per share, generating total gross proceeds of $8,280,000 [102]. - The company anticipates needing additional financing to support technology development and ongoing operations, as it is currently operating at a loss [99]. - The potential proceeds from outstanding warrants could amount to up to $15,694,288, although there is no assurance these will be exercised [103]. - The company has limited insurance coverage, which may not cover significant claims, potentially impacting financial condition [115]. Intellectual Property - The company has been granted 27 patents and 19 design patents, with additional patents pending, supporting its intellectual property strategy [54]. - The company faces challenges in protecting its intellectual property, which could affect its competitive position and revenue [116]. Market Strategy - Know Labs, Inc. is building an internal sales and marketing team to prepare for the launch of its products and explore various market entry strategies [48]. - The competitive landscape includes large global technology companies, legacy providers, and new entrants, with Know Labs, Inc. believing its Bio-RFID technology offers a unique advantage in the market [49]. - The company aims to monetize its AI deep learning platform, exploring new applications to generate revenue for further development of its diagnostic technology [53]. Operational Challenges - The company is actively monitoring the impact of COVID-19 on its operations, which has caused supply chain delays and increased costs due to inflation [96]. - The company relies on external resources for engineering and product development, which could impact its ability to commercialize technology successfully [107]. - The company relies on key personnel, including its Chairman and CEO, and failure to retain them could adversely affect business operations [114]. - The company may face significant costs related to compliance with corporate governance and internal control requirements, which are expected to remain substantial [138]. - Cybersecurity risks pose a threat to the integrity and availability of sensitive information, necessitating ongoing investment in security measures [137]. Employee and Corporate Structure - The company has 16 full-time employees as of September 30, 2022, supplemented by consulting firms and contractors [62]. - The company has anti-takeover provisions in its bylaws designed to delay or prevent unsolicited acquisition attempts [212][215]. - The company has elected not to be governed by certain Nevada statutes that could limit third-party acquisitions of its stock [213][214]. Stock and Shareholder Information - As of September 30, 2022, the company had 48,156,062 shares of common stock issued and outstanding, with options and warrants potentially diluting future earnings per share [144]. - The company is authorized to issue up to 200,000,000 shares of common stock, which could lead to substantial dilution of existing stockholders' ownership [146]. - The market price of the company's common stock has been volatile, influenced by various market and industry factors, which may adversely affect stockholder investments [143]. - The company has never declared or paid cash dividends on its common stock and intends to retain all available funds for business operations [168].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation or organization) Nevada 90 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or orga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation or organization) Nevad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended September 30, 2021 ☐ TRANSACTION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transaction period from ________ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation or organization) Nevada 90-0273142 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF TH ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation or organization) (Former n ...

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Commission File number 000-30262 KNOW LABS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or other jurisdiction of incorporation or orga ...

Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT For the transition period from _______ to ________ Indicate by check mark whether the registrant (1) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (FEE REQUIRED) For the fiscal year ended September 30, 2020 ☐ TRANSACTION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (NO FEE REQUIRED) For the transaction period from ________ to ________ Commission File number 000-30262 KNOW LABS, INC. (Exact name of registrant as specified in charter) Nevada 90-0273142 (State or othe ...